Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells = Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells

다국어 초록 (Multilingual Abstract)

Triple-negative breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes. Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients. 17-Demethoxy-reblastatin (17-DR), a novel nonbenzoquinone- type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity. In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated. These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells. Down-regulation of the key Hsp90-dependent tumor-driving molecules, such as RIP1 and MMP-9, by 17-DR may be related to these effects. Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.

참고문헌 (Reference)

1 Groblewska M, "The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer" 50 : 12-19, 2012

2 Da Silva VC, "The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics" 75 : 2790-2802, 2012

3 Zhang H, "Targeting multiple signal transduction pathways through inhibition of Hsp90" 82 : 488-499, 2004

4 Wrona IE, "Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90" 75 : 2820-2835, 2010

5 Han HZ., "Research in progress of triple negative breast cancer molecular targeted therapy" 17 : 470-474, 2012

6 Kim W, "Rational biosynthetic engineering for optimization of geldanamycin analogues" 10 : 1243-1251, 2009

7 Mosmann T, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays" 65 : 55-63, 1983

8 Wu ZS, "Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer" 122 : 2050-2056, 2008

9 Cheng-Zhu Wu, "New Geldanamycin Analogs from Streptomyces hygroscopicus" 한국미생물·생명공학회 22 (22): 1478-1481, 2012

10 Kim W, "Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring" 8 : 1491-1494, 2007

11 Mosser DD, "Molecular chaperones and the stress of oncogenesis" 23 : 2907-2918, 2004

12 Whitesell L, "Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation" 91 : 8324-8328, 1994

13 Hong YS, "Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin" 126 : 11142-11143, 2004

14 Chiosis G, "Hsp90: the vulnerable chaperone" 9 : 881-888, 2004

15 Whitesell L, "Hsp90 and the chaperoning of cancer" 5 : 761-772, 2005

16 Zhao S, "High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC)patients" 30 : 335-, 2013

17 Sankhala KK, "Heat shock proteins: a potential anticancer target" 12 : 2001-2008, 2011

18 Messaoudi S, "Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010" 21 : 1501-1542, 2010

19 Wu CZ, "Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase" 78 : 7680-7686, 2012

20 Bryan BB, "Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer" 19 : 617-621, 2006

21 Shin, Jin Chul, "Characterization of Tailoring Genes Involved in the Modification ofGeldanamycin Polyketide in Streptomyces hygroscopicus JCM4427" 한국미생물·생명공학회 18 (18): 1101-1108, 2008

22 Amend K, "Breast cancer in African-American women: differences in tumor biology from European-American women" 66 : 8327-8330, 2006

23 Cheng Q, "Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer" 14 : 62-, 2012

24 Xing H, "Activation of fibronectin/PI3K/Akt leads to chemoresistance to docetaxel by regulating surviving protein expression in ovarian and breast cancer" 261 : 108-119, 2008

25 Baichwal VR, "Activate NF-κB or die?" 7 : 94-96, 1997

26 Heath EI, "A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer" 14 : 7940-7946, 2008

27 Kamal A, "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors" 69 : 5898-5903, 2003

28 Kim MS, "17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion" 6 : 1657-1665, 2008